Pyxis Oncology (PYXS) FCF Margin (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly FCF Margin came in at 94.46% in Q4 2025, up 84.57% quarter-over-quarter from 612.16% in Q2 2025.
Powered by 
Analysis
Pyxis Oncology (PYXS) FCF Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported FCF Margin for 2 consecutive years, with 94.46% the latest figure, recorded in Q4 2025.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 94.46% in Q4 2025; TTM through Dec 2025 was 458.23%, a 9958.0% decrease from a year earlier, with the FY2025 full-year figure at 458.3%, down 9964.0% from the prior year.
- FCF Margin was 94.46% for Q4 2025 at Pyxis Oncology, up from 612.16% in the prior quarter.
- Over five years, FCF Margin peaked at 94.46% in Q4 2025 and troughed at 612.16% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn | -18,629.40% |
| 10 | Pyxis Oncology | 206.05 Mn | 173.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -94.46% |
| Jun 30, 2025 | -612.16% |
| Mar 31, 2024 | -129.73% |